Form 4: Edgewise Therapeutics CFO Receives Stock Grant
Insider Transaction (Form 4)
Michael Nofi, Chief Financial Officer of Edgewise Therapeutics, Inc., reported multiple transactions in common stock on August 12, 2026.
Summary
- Grant/award: acquired 24,375 Restricted Stock Units on August 12, 2026; holds 24,375 after (Direct).
- Grant/award: acquired 48,750 Stock Option (Right to Buy) on August 12, 2026; holds 48,750 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Michael Nofi — Officer (Chief Financial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-12 | Grant/award | Restricted Stock Units | 24,375 | — | — | 24,375 |
| 2026-08-12 | Grant/award | Stock Option (Right to Buy) | 48,750 | — | — | 48,750 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-12 | Grant/award (24,375 shares) |
| 2026-08-12 | Grant/award (48,750 shares) |
Keywords
insider transaction, Form 4, EWTX, Edgewise Therapeutics, Inc., neutral, Michael Nofi
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.